Neuroendocrine tumors are a heterogeneous group of tumors, but they generally express a high number of somatostatin receptors on their cell membranes. This receptor is a target for somatostatin analogs, which can be labeled with radionuclides for both imaging and therapy.
In this thesis, several aspects regarding the imaging and therapy of neuroendocrine tumors with radiolabeled somatostatin analogs are discussed. The efficacy and toxicity of 177 Lu-DOTATATE in patients with inoperable and/or metastatic GEP and bronchial NETs was evaluated.
We identified several pitfalls in imaging and therapy of patients with NETs. Also, the best way to detect progression after PRRT with 177 Lu-DOTATATE was evaluated.

Additional Metadata
Keywords PRRT, neuroendocrine tumors, somatostatin receptor
Promotor D.J. Kwekkeboom (Dirk Jan) , W.W. de Herder (Wouter)
Publisher Erasmus University Rotterdam
Persistent URL hdl.handle.net/1765/101850
Citation
Brabander, T. (2017, October 11). Imaging and Therapy of Neuroendocrine Tumors with Radiolabeled Somatostatin Analogs. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/101850